Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Noven Acquires Minivelle Rights | Contract Pharma

What are you searching for?

Sign in
Breaking News

Noven Acquires Minivelle Rights

Transdermal system will be manufactured at Miami facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the U.S. and Canada from Novogyne Pharmaceuticals, a women’s health joint venture between Noven and Novartis. Financial terms were not disclosed.
 
Noven will market and sell Minivelle through the Women’s Health unit of its subsidiary, Noven Therapeutics, LLC. Noven developed the Minivelle patch using its DOT Matrix transdermal delivery technology, and the product will be manufactured at its Miami, FL facility.
 
Minivelle is approved by the FDA for the treatment of moderate to severe vasomotor symptoms due to menopause. Noven expects that Minivelle will be available in the U.S. in 1Q13.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics